-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15

Benzinga·09/30/2026 09:56:41
Listen to the news
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14.5 to $15.